UroGen Pharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a URGN research report →
Range $44 – $75
Price Chart
About the company
UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
- CEO
- Elizabeth Barrett
- IPO
- 2017
- Employees
- 300
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on URGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36B
- P/E
- -20.95
- Fwd P/E
- 11.08
- PEG
- -0.19
- P/S
- 5.42
- P/B
- -11.16
- EV/EBITDA
- -36.78
- Div Yield
- 0.00%
- Gross Margin
- 91.41%
- Op Margin
- -12.36%
- Net Margin
- -26.27%
- ROE
- 53.97%
- ROIC
- -15.47%
Latest fiscal year · YoY change
- Revenue
- $109.79M+21.4%
- Gross Profit
- $97.34M+19.4%
- Op Income
- $-124,863,000
- Net Income
- $-153,494,000-21.0%
- EPS
- $-3.19-7.8%
- OCF Growth
- -67.9%
- FCF Growth
- -67.7%
- 52W High
- $50.81
- 52W Low
- $16.50
- 50D MA
- $35.89
- 200D MA
- $31.89
- Beta
- 1.64
- RSI (14)
- 51
- Avg Volume
- 1.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
UroGen reported a strong Q3 2026 with Zosturi driving growth, Jelmyto pressured by trial-related headwinds, and management guiding to profitability in Q4.· November 4, 2026
- Zosturi net product revenue was $68 million, up 35% sequentially, with management saying repeat utilization, broader adoption, and community practice penetration are strengthening.
- Total revenue was $89 million versus $27.5 million a year ago; net loss narrowed to $1.5 million, or $0.03 per share, from $33.3 million, or $0.69 per share.
- Jelmyto revenue was $21 million versus $22 million in Q2, hit by an approximately $1.5 million gross-to-net true-up and lower starts tied to competing clinical trials.
- Management said UGN-103 was accepted by the FDA with a PDUFA date of June 14, 2027, and plans a 2028 commercial launch if approved with a permanent J-code.
- The company ended the quarter with $90.5 million in cash, cash equivalents and marketable securities and expects to reach profitability and positive cash flow in Q4 2026.
Total revenue was $89 million in Q3 2026 versus $27.5 million in Q3 2025, driven by the Zosturi launch. Zosturi generated $68 million in net product revenue, up 35% sequentially quarter over quarter. Jelmyto generated $21 million in net product revenue versus $22 million in Q2, including a one-time unfavorable gross-to-net adjustment of approximately $1.5 million tied to the CMS discarded drug provision true-up. Research and development expense was $26 million versus $14 million a year ago, and SG&A was $47.2 million versus $37.6 million. Net loss was $1.5 million, or $0.03 per basic and diluted share, versus $33.3 million, or $0.69 per share, in Q3 2025. Cash, cash equivalents and marketable securities totaled $90.5 million at 9/30/2026. Full-year Jelmyto revenue guidance was lowered to approximately $90 million, and full-year operating expense guidance was maintained at $260 million to $270 million, with expenses expected toward the upper end of the range. Management said it expects Q4 revenue to grow sequentially and expects to achieve profitability and positive cash flow in Q4 2026.
Liz Barrett said the quarter showed strong execution, with Zosturi scaling faster as repeat use, physician adoption, and community practice penetration improved. She emphasized that Zosturi’s surgery-free profile is resonating with physicians and patients, and she framed the company’s strategy around commercial execution, life-cycle expansion, and pipeline innovation. Her tone was upbeat and confident, but she also acknowledged that launch dynamics will remain uneven in the near term and that broader acceleration likely takes time.
Christopher Degnan highlighted the core financial picture: $89 million of revenue, $26 million of R&D, $47.2 million of SG&A, and $90.5 million of quarter-end cash, cash equivalents and marketable securities. He also cited a $4.8 million PDUFA fee and a $4 million investment in IntraGel as part of the quarter’s cash burn. On capital allocation, he said the company expects to fund the business through profitability with existing resources and anticipates positive cash flow in Q4 2026. He also updated full-year Jelmyto revenue guidance to approximately $90 million and said operating expenses should land toward the high end of the $260 million to $270 million range.
Analysts pressed management on how broad Zosturi usage is versus the original study population, and management said doctors often start with more heavily pretreated patients but claims data show use across the board, including after one and two prior TURBTs. They were also asked about launch seasonality and whether Q3 softness mattered; management said the impact was hard to quantify and likely not large because demand rebounded quickly. Other questions focused on the pace of Zosturi site activation, repeat prescribers, and whether FDA would want more data for UGN-103; management said no additional comparative data request has been made, only the planned 12-month durability update. On IntraGel, management said it would look for positive Phase 2 data before deciding whether to exercise its option on the cisplatin candidate.
The bull case is that Zosturi appears to be gaining traction quickly, with $68 million in Q3 revenue, 662 unique prescribers, and repeat prescribers reaching 50% of total writers. Management repeatedly said adoption is broadening into community practices and that the business still has a large untapped urologist universe, leaving room for continued growth. The company also has multiple future catalysts in UGN-103, UGN-104, UGN-501, and the IntraGel collaboration.
The main risks discussed were launch seasonality, holiday-related fourth-quarter slowdown, and the fact that Zosturi adoption is still early and methodical rather than broad-based. Jelmyto faces competitive trial headwinds in low-grade UTUC, and management said those pressures could continue into 2027. The company is also spending heavily on launch and pipeline work, with operating expenses expected toward the high end of guidance, so execution must continue to offset these investments.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.8%
- Shares Outstanding
- 49.05M
- Float Shares
- 43.58M
of shares held by institutions
199 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 4.54M | 0 |
| Blackrock, Inc. | 3.20M | ▲ 355.89K |
| Morgan Stanley | 2.58M | ▲ 16.32K |
| Kynam Capital Management, LP | 2.43M | ▲ 186.81K |
| Jefferies Financial Group Inc. | 2.20M | 0 |
| Sg Americas Securities, LLC | 2.05M | ▲ 395.06K |
| Acorn Capital Advisors, LLC | 1.67M | 0 |
| Point72 Asset Management, L.P. | 1.53M | ▲ 1.53M |
| Frontier Capital Management Co LLC | 1.51M | ▲ 194.44K |
| Opaleye Management Inc. | 1.44M | ▲ 10.00K |
| American Century Companies Inc | 1.38M | ▼ 310.42K |
| Menora Mivtachim Holdings Ltd. | 1.15M | 0 |
Held by 204 ETFs
Biggest fund positions in URGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 26 | Degnan Chris | other | 4,483 |
| Oct 8, 26 | Degnan Chris | sell | 2,202 |
| Oct 8, 26 | Degnan Chris | other | 4,483 |
| Sep 7, 26 | Schoenberg Mark | other | 1,667 |
| Sep 8, 26 | Schoenberg Mark | sell | 871 |
| Sep 7, 26 | Schoenberg Mark | other | 1,667 |
| Sep 7, 26 | Smith Jason Drew | other | 3,334 |
| Sep 8, 26 | Smith Jason Drew | sell | 1,519 |
| Sep 7, 26 | Smith Jason Drew | other | 3,334 |
| Aug 26, 26 | Robinson James A. Jr. | other | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our URGN coverage
Recent articles, reports, and earnings notes.
No research on URGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate URGN report →Implied Volatility Surging for Urogen Pharma Stock Options
zacks.com · Nov 19
UroGen: Opportunity Builds As Rough Patch Gets Brutal
seekingalpha.com · Nov 9
Urogen Pharma Q3 Earnings Call Highlights
marketbeat.com · Nov 4
The Gel That Became a Business
fool.com · Nov 4
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
globenewswire.com · Nov 4
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.